Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Mantle-Cell 7Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell, Marginal Zone 3Leukemia, B-Cell 3Leukemia 3Lymphoma, Follicular 2Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

Rituximab 7zanubrutinib 6venetoclax 4ibrutinib 3Dexamethasone 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2Blood Specimen Collection 2Biopsy 2Bendamustine Hydrochloride 2pirtobrutinib 1obinutuzumab 1Positron-Emission Tomography 1Lenalidomide 1Exercise 1Diet 1CT-P10 1Bortezomib 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Waldenstrom Macroglobulinemia × pirtobrutinib × Clear all
NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡